logo
DMG Blockchain Solutions Inc. Announces MOU to Purchase 10-Megawatt Data Center Infrastructure

DMG Blockchain Solutions Inc. Announces MOU to Purchase 10-Megawatt Data Center Infrastructure

VANCOUVER, British Columbia, Feb. 24, 2025 (GLOBE NEWSWIRE) -- DMG Blockchain Solutions Inc. (TSX-V: DMGI) (OTCQB: DMGGF) (FRANKFURT: 6AX) ('DMG' or the 'Company'), a vertically integrated blockchain and data center technology company, announces it has signed a memorandum of understanding (MOU) with an undisclosed counterparty ('Counterparty') to purchase the infrastructure for a prefabricated 10-megawatt air-cooled data center ('PDC') that meets Sensitive Compartmented Information Facility (SCIF) specifications (which is generally a military requirement) for its deployment of Generative Artificial Intelligence (Gen AI) computation facilities. DMG and Counterparty have agreed to work towards a definitive agreement within the next 90 days, during which time DMG will perform its due diligence as a follow-up to its already performed initial inspection of the PDC at Counterparty's site. DMG will issue an additional news release related to the final structure and terms of the potential transaction, and other material information if and when it becomes available.
Upon execution of the definitive agreement, DMG would pay Counterparty for the PDC US$5 million as an upfront payment and the balance of the to-be-agreed-upon price based on future DMG revenue resulting from Gen AI computing off-take agreements as part of vendor financing being offered to DMG. Revenue from off-take agreements may be derived from either GPUs that DMG purchases or the colocation of customer-purchased GPUs. DMG is currently focused on securing off-take agreements, which may be sourced from entities that require SCIF requirements, such as federal government agencies/departments, non-governmental entities (potentially with enterprise SCIF requirements), Counterparty and/or with other parties with whom the Company has a relationship to develop Gen AI business opportunities, which may be outside of Canada.
DMG intends to deploy the PDC at one or more locations, as the PDC can be partitioned into smaller units due to its modular nature. While the infrastructure forms the basis for a Gen AI data center, it does not include medium-voltage power distribution, battery storage or backup power generation, the configuration and amount of which have yet to be determined. Additionally, the PDC is not facilitated with computing, networking nor storage systems, all of which will need to be installed to realize revenue from off-take agreements.
DMG's CEO Sheldon Bennett stated, 'This MOU catalyzes our entry into Generative AI in a very meaningful way. Not only does the PDC shorten our time to deployment by at least a year, but it also gives us the needed credibility as a new AI entrant to secure off-take agreements in a timely manner. Given the SCIF (military-grade) nature of the infrastructure, we will be focused on off-take opportunities that prioritize this need, as we believe we can garner a revenue premium for offering this capability. This MOU also enables us to proceed with our Gen AI strategy in a most-capital efficient manner, helping us to maximize our return to shareholders.'
About DMG Blockchain Solutions Inc.
DMG is a publicly traded and vertically integrated blockchain and data center technology company that manages, operates and develops end-to-end digital solutions to monetize the digital asset and artificial intelligence compute ecosystems. Systemic Trust Company, a wholly owned subsidiary of DMG, is an integral component of DMG's carbon-neutral Bitcoin ecosystem, which enables financial institutions to move bitcoin in a sustainable and regulatory-compliant manner.
Follow @dmgblockchain on X and subscribe to DMG's YouTube channel.
For further information, please contact:
On behalf of the Board of Directors,
Sheldon Bennett, CEO & Director
Tel: +1 (778) 300-5406
Email: [email protected]
Web: www.dmgblockchain.com
For Investor Relations:
For Media Inquiries:
Chantelle Borrelli
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.
Cautionary Note Regarding Forward-Looking Information
This news release contains forward-looking information or statements based on current expectations. Forward-looking statements contained in this news release include the execution of a definitive agreement for the MDC and the timing thereof, the expected benefits and outcomes of the MDC including the potential Gen AI computing off-take agreements, the Company's strategy for growth, the planned monetization of certain product and service offerings, developing and executing on the Company's products, services and business plans, the launch of products and services, events, courses of action, and the potential of the Company's technology and operations, among others, are all forward-looking information.
Future changes in the Bitcoin network-wide mining difficulty or Bitcoin hashrate may materially affect the future performance of DMG's production of bitcoin, and future operating results could also be materially affected by the price of bitcoin and an increase in hashrate and mining difficulty.
Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations, or intentions regarding the future. Such information can generally be identified by the use of forwarding-looking wording such as 'may', 'expect', 'estimate', 'anticipate', 'intend', 'believe' and 'continue' or the negative thereof or similar variations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including but not limited to, market and other conditions, volatility in the trading price of the common shares of the Company, business, economic and capital market conditions; the ability to manage operating expenses, which may adversely affect the Company's financial condition; the ability to remain competitive as other better financed competitors develop and release competitive products; regulatory uncertainties; access to equipment; market conditions and the demand and pricing for products; the demand and pricing of bitcoin; security threats, including a loss/theft of DMG's bitcoin; DMG's relationships with its customers, distributors and business partners; the inability to add more power to DMG's facilities; DMG's ability to successfully define, design and release new products in a timely manner that meet customers' needs; the ability to attract, retain and motivate qualified personnel; competition in the industry; the impact of technology changes on the products and industry; failure to develop new and innovative products; the ability to successfully maintain and enforce our intellectual property rights and defend third-party claims of infringement of their intellectual property rights; the impact of intellectual property litigation that could materially and adversely affect the business; the ability to manage working capital; and the dependence on key personnel. DMG may not actually achieve its plans, projections, or expectations. Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which the Company will operate in the future, including the demand for its products, the ability to successfully develop software, that there will be no regulation or law that will prevent the Company from operating its business, anticipated costs, the ability to secure sufficient capital to complete its business plans, the ability to achieve goals and the price of bitcoin. Given these risks, uncertainties, and assumptions, you should not place undue reliance on these forward-looking statements. The securities of DMG are considered highly speculative due to the nature of DMG's business. For further information concerning these and other risks and uncertainties, refer to the Company's filings on www.sedarplus.ca. In addition, DMG's past financial performance may not be a reliable indicator of future performance.
Factors that could cause actual results to differ materially from those in forward-looking statements include, failure to obtain regulatory approval, the continued availability of capital and financing, equipment failures, lack of supply of equipment, power and infrastructure, failure to obtain any permits required to operate the business, the impact of technology changes on the industry, the impact of viruses and diseases on the Company's ability to operate, secure equipment, and hire personnel, competition, security threats including stolen bitcoin from DMG or its customers, consumer sentiment towards DMG's products, services and blockchain technology generally, failure to develop new and innovative products, litigation, adverse weather or climate events, increase in operating costs, increase in equipment and labor costs, equipment failures, decrease in the price of Bitcoin, failure of counterparties to perform their contractual obligations, government regulations, loss of key employees and consultants, and general economic, market or business conditions. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The reader is cautioned not to place undue reliance on any forward-looking information. The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Additionally, the Company undertakes no obligation to comment on the expectations of or statements made by third parties in respect of the matters discussed above.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

South Africa Employee Benefits 2025: Comprehensive Overview of State and Private Employee Benefits in South Africa
South Africa Employee Benefits 2025: Comprehensive Overview of State and Private Employee Benefits in South Africa

Yahoo

time14 minutes ago

  • Yahoo

South Africa Employee Benefits 2025: Comprehensive Overview of State and Private Employee Benefits in South Africa

Unlock comprehensive insights into South Africa's employee benefits landscape with this in-depth report. Explore state, compulsory, and private benefits, understand regulatory frameworks, and discover the roles of key institutions. Ideal for strategic decision-making and understanding South Africa's social security system. Dublin, June 09, 2025 (GLOBE NEWSWIRE) -- The "Employee Benefits in South Africa 2025" report has been added to report provides in-depth industry analysis, information, and insights of the employee benefits in South Africa, including an overview of the state and compulsory benefits in South Africa, detailed information about the private benefits in South Africa, insights on various central institutions responsible for the administration of the different branches of social security and the regulatory framework of the employee benefits in South Africa has a well-developed social security system, which covers employees and their dependents, as well as unemployed persons and individuals. The Department of Labor (DoL) is the central labor administration body and is regulated by the Ministry of Labor. The South African social security system is composed of three pillars: the non-contributory pillar (taxed pillar), the contributory pillar, and the private voluntary pillar. The contributory pillar includes social insurance, while the non-contributory pillar includes social assistance and social relief distress. The private voluntary pillar covers pensions, short-term, work-injury, and healthcare benefits and is usually voluntary, but can become obligatory based on a company's policy, work, industry, and Highlights South African Social Security Agency, Financial Sector Conduct Authority and Department of Labor are responsible for the functioning of the overall social security system in South Africa. A person's national insurance contribution is determined based on their income. An insured person who is unemployed or unable to work and whose benefits have been exhausted is entitled to credited contribution. In South Africa, employers provide supplementary pension benefits as social security benefits. This report provides a detailed analysis of employee benefits in South Africa It offers a detailed analysis of the key government-sponsored employee benefits, along with private benefits It covers an exhaustive list of employee benefits, including retirement benefits, death in Service, Short-term Sickness Benefit, medical benefits, workmen's compensation insurance, maternity and paternity benefits, unemployment benefit, Family Benefit, Grant-in-Aid, Social Relief distress, leaves and holidays and private benefits It highlights the economic and regulatory situations relating to employee benefits in South Africa Reasons to Buy Make strategic decisions using in-depth information related to employee benefits in the country Assess employee benefits of the market, including state and compulsory benefits and private benefits Gain insights into the key employee benefit schemes offered by private employers in the country Gain insights into key organizations governing employee benefits market, and their impact on companies Key Topics Covered: 1. Executive Summary2. Introduction3. Country Statistics4. Overview of Employee Benefits in South Africa5. Regulations6. State and Compulsory Benefits6.1 Retirement Benefits Introduction Eligibility Benefits Payment options Contribution 6.2 Death in Service Introduction Eligibility Benefits Payment options Contribution 6.3 Long-Term Disability Benefits Introduction Eligibility Benefits Payment options Contribution 6.4 Short-Term Disability Benefits Introduction Eligibility Benefits Payment options Contribution 6.5 Medical Benefits Introduction Eligibility Benefits Payment options Contribution 6.6 Workers' Compensation insurance Introduction Eligibility Benefits Payment options Contribution 6.7 Maternity and Paternity Benefits Introduction Eligibility Benefits Payment options Contribution 6.8 Other Benefits Unemployment Benefit Family Benefits Grant in Aid Social Relief distress Leaves and Holidays 7. Private Benefits7.1 Retirement Benefits7.2 Death Benefits7.3 Disability Benefits7.4 Medical Benefits7.5 Accidental Death and Dismemberment Benefits7.6 Other BenefitsFor more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

High Throughput Process Development Strategic Business Report 2025-2030: Increasing Focus on Speed and Efficiency in Drug Discovery Expands Market Opportunities
High Throughput Process Development Strategic Business Report 2025-2030: Increasing Focus on Speed and Efficiency in Drug Discovery Expands Market Opportunities

Yahoo

time14 minutes ago

  • Yahoo

High Throughput Process Development Strategic Business Report 2025-2030: Increasing Focus on Speed and Efficiency in Drug Discovery Expands Market Opportunities

The global High Throughput Process Development (HTPD) market, pivotal for the biopharmaceutical industry, is projected to grow from $15.3 billion in 2024 to $24.6 billion by 2030, at a CAGR of 8.3%. Key drivers include technological innovations in automation and data analytics. The market is segmented by product types, including consumables and software, with major growth forecasted in regions such as China and the U.S. The report offers insights into market trends, regional analysis, and profiles leading companies like Agilent Technologies and Danaher Corporation. High Throughput Process Development Market Dublin, June 09, 2025 (GLOBE NEWSWIRE) -- The "High Throughput Process Development - Global Strategic Business Report" report has been added to global market for High Throughput Process Development was valued at US$15.3 Billion in 2024 and is projected to reach US$24.6 Billion by 2030, growing at a CAGR of 8.3% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the High Throughput Process Development market. The growth in the high throughput process development market is driven by several factors, including the increasing complexity of biologic drugs, the rising demand for personalized medicines, and advancements in automation and data analytics. As the biopharmaceutical industry shifts toward more complex therapeutics, such as gene and cell therapies, the need for efficient process optimization is more critical than ever. HTPD allows companies to streamline the development of these therapies, reducing both time and costs. The growing demand for biosimilars, which require rapid process development to compete with branded biologics, is also contributing to market growth. Additionally, the adoption of automation and machine learning in process development is further enhancing the efficiency and accuracy of bioprocess optimization, driving the market's throughput process development (HTPD) is a critical tool in the biopharmaceutical industry, enabling faster, more efficient development of biologic drugs. HTPD involves the use of automated, miniaturized experiments that allow researchers to test multiple process conditions simultaneously, significantly accelerating the optimization of production processes for therapeutic proteins, vaccines, and monoclonal antibodies. The ability to screen numerous variables at once reduces the time and resources needed to scale up bioprocesses, from lab-scale to commercial manufacturing. As biopharmaceutical companies face increasing pressure to reduce costs and bring therapies to market faster, HTPD has become indispensable in ensuring both process efficiency and product Are Technological Innovations Shaping High Throughput Process Development?Technological innovations, particularly in automation, robotics, and data analytics, have revolutionized high throughput process development. Automation systems now allow for the simultaneous running of hundreds of experiments, enabling researchers to optimize cell culture conditions, purification processes, and formulation strategies more efficiently. The integration of advanced data analytics and machine learning into HTPD platforms has further enhanced process optimization, allowing for predictive modeling and real-time decision-making. Microfluidic technologies, which allow for the precise control of small volumes of liquids, are also playing a critical role in reducing reagent use and increasing the speed of bioprocess optimization. These technologies are enabling biopharmaceutical companies to streamline their development timelines and reduce production Do Market Segments Define the Growth of the High Throughput Process Development Market?Product types include consumables, software, and instruments, with consumables like reagents and microplates holding the largest market share due to their constant need in HTPD workflows. Services such as contract research and process development outsourcing are also expanding, as biopharmaceutical companies increasingly seek external expertise to accelerate drug development. The biopharmaceutical industry, particularly companies focused on biologics such as monoclonal antibodies, is the primary end-user of HTPD, as it enables rapid scale-up from R&D to manufacturing. Other key users include academic and research institutes involved in biotechnology Scope Report Features: Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030. In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa. Company Profiles: Coverage of players such as Agilent Technologies, Aurora Biomed, Axxam S.P.A., Bio-Rad Laboratories, Danaher Corporation and more. Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments. Key Insights: Market Growth: Understand the significant growth trajectory of the Monoclonal Antibodies segment, which is expected to reach US$17.8 Billion by 2030 with a CAGR of a 9.1%. The Other Molecule Types segment is also set to grow at 6.5% CAGR over the analysis period. Regional Analysis: Gain insights into the U.S. market, valued at $3.9 Billion in 2024, and China, forecasted to grow at an impressive 12.6% CAGR to reach $6.4 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific. Segments Molecule Type (Monoclonal Antibodies, Other Molecule Types) Component (Tools & Systems, Consumables, Software, Other Components) Technology (Chromatography, Ultraviolet-Visible Spectroscopy, Other Technologies) End-Use (Biopharmaceutical Companies, Contract Research Organizations, Academic Research Institutes) Tariff Impact Analysis: Key Insights for 2025What's Included in This Edition: Tariff-adjusted market forecasts by region and segment Analysis of cost and supply chain implications by sourcing and trade exposure Strategic insights into geographic shifts Buyers receive a free July 2025 update with: Finalized tariff impacts and new trade agreement effects Updated projections reflecting global sourcing and cost shifts Expanded country-specific coverage across the industry Key Attributes: Report Attribute Details No. of Pages 89 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $15.3 Billion Forecasted Market Value (USD) by 2030 $24.6 Billion Compound Annual Growth Rate 8.3% Regions Covered Global Key Topics Covered: MARKET OVERVIEW Influencer Market Insights Tariff Impact on Global Supply Chain Patterns Global Economic Update High Throughput Process Development - Global Key Competitors Percentage Market Share in 2024 (E) Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E) MARKET TRENDS & DRIVERS Rising Demand for Biopharmaceuticals Drives Growth in High Throughput Process Development Technological Advancements in Automation and Robotics Propel Innovation in High Throughput Process Development Increasing Focus on Speed and Efficiency in Drug Discovery Expands Addressable Market for High Throughput Solutions Growing Adoption of High Throughput Technologies in Vaccine Development Spurs Market Growth Surge in Demand for Personalized Medicine Strengthens Business Case for High Throughput Process Development Increasing Use of High Throughput Screening in Protein and Antibody Discovery Expands Market Potential Technological Innovations in Microfluidics and Lab Automation Propel Market Innovation Growing Focus on Reducing Time-to-Market for Pharmaceuticals Drives Adoption of High Throughput Processes Rising Use of Artificial Intelligence (AI) in High Throughput Data Analysis Strengthens Competitive Advantage Increasing Focus on Process Optimization and Scalability in Biopharmaceutical Production Drives Innovation Rising Demand for High Throughput Analytical Techniques in Quality Control Expands Market Opportunities FOCUS ON SELECT PLAYERS:Some of the 33 companies featured in this report Agilent Technologies Aurora Biomed Axxam S.P.A. Bio-Rad Laboratories Danaher Corporation Eppendorf GE Healthcare Hamilton Company Merck Millipore Perkinelmer Sartorius Stedim Biotech Tecan Group Thermo Fisher Scientific, Inc. For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment High Throughput Process Development Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

VeriSilicon's AI-ISP Custom Chip Solution Enables Mass Production of Customer's Smartphones
VeriSilicon's AI-ISP Custom Chip Solution Enables Mass Production of Customer's Smartphones

Yahoo

time22 minutes ago

  • Yahoo

VeriSilicon's AI-ISP Custom Chip Solution Enables Mass Production of Customer's Smartphones

Providing architecture design, software-hardware co-development, and mass production support, and enhancing AI-powered imaging capabilities in smart devices SHANGHAI, June 09, 2025--(BUSINESS WIRE)--VeriSilicon ( recently announced that its AI-ISP custom chip solution has been successfully adopted in a customer's mass-produced smartphones, reaffirming the company's comprehensive one-stop custom silicon service capabilities in AI vision processing. VeriSilicon's AI-ISP custom chip solution can integrate proprietary or third-party Neural Network Processing Unit (NPU) IP and Image Signal Processing (ISP) IP. By combining traditional image processing techniques with AI algorithms, it significantly enhances image and video clarity, dynamic range, and environmental adaptability. The chip solution offers flexible configurations with RISC-V or Arm-based processors, supports MIPI image input/output interfaces, provides LPDDR5/4X memory integration capability, and is compatible with common peripheral interfaces such as UART, I2C, and SDIO. This makes the solution highly adaptable for deployment across various applications including smartphones, surveillance systems, and automotive electronics. For this collaboration, VeriSilicon designed a low-power AI-ISP system-on-chip (SoC) based on the RISC-V architecture, tailored to the customer's specific requirements. It also included a FreeRTOS real-time Software Development Kit (SDK). The customized SoC was fully optimized for seamless interoperability with the customer's main processor platform and has since been successfully deployed in multiple smart devices, achieving large-scale production. This success highlights VeriSilicon's robust capabilities in heterogeneous computing, software-hardware co-optimization, and system-level integration and verification. "AI-powered imaging has become a key differentiator in the competitive smartphone market, driving increasing demand for high-performance and low-power image processing solutions," said Wiseway Wang, Executive Vice President and General Manager of the Custom Silicon Platform Division at VeriSilicon. "With full-spectrum capabilities ranging from IP licensing and chip architecture design to system-level software and hardware development, tape-out, packaging and testing, as well as mass production, VeriSilicon offers end-to-end custom silicon services leveraging its extensive design service experience and proven mass production capabilities. The successful mass production of this customer's chip further validates our strength in high-end silicon design services. Moving forward, we will continue to innovate and improve our offerings, empowering customers to accelerate the launch of differentiated products with efficient, high-quality custom chip solutions." About VeriSilicon VeriSilicon is committed to providing customers with platform-based, all-around, one-stop custom silicon services and semiconductor IP licensing services leveraging its in-house semiconductor IP. For more information, please visit: View source version on Contacts Media Contact: press@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store